Pharma Pulse 4/22/24: Is Japan Leading a New Digital Health Movement? The Smartest Way to Use AI at Work & more

Is Japan Leading a New Digital Health Movement?

Factors that contribute to Japan's prominent position in the rapidly evolving field of digital therapeutics and why it matters to the global life sciences industry.

Gap in Medicaid Impacts Access to Services for Justice-Involved Patients

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases.

The Smartest Way to Use AI at Work

Generative AI tools can help you get ahead in the office—if you know how to use them.

US FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO®(vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

ENTYVIO is now available in the US in both IV and subcutaneous administrations for maintenance treatment of adults with moderately to severely active ulcerative colitis or Crohn’s Disease.

Michael L. Kyle, M.D. on LinkedIn:

The data in this interview with George Hampton with Pharmaceutical Executive speaks volumes. It demonstrates the positive impact our drug has had on weight loss and obesity. A big thank you to our dedicated team at Currax Pharmaceuticals LLC for their relentless commitment to advancing healthcare and patient safety. 

https://bit.ly/49KFVVc

#TeamCurrax #ObesityPrevention #WeightLoss

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs